Frank Verwiel - Net Worth and Insider Trading
Frank Verwiel Net Worth
The estimated net worth of Frank Verwiel is at least $298,834 dollars as of 2024-11-13. Frank Verwiel is the Director of Intellia Therapeutics Inc and owns about 17,948 shares of Intellia Therapeutics Inc (NTLA) stock worth over $298,834. Details can be seen in Frank Verwiel's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Frank Verwiel has not made any transactions after 2024-06-17 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Frank Verwiel
Frank Verwiel Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Frank Verwiel owns 3 companies in total, including Intellia Therapeutics Inc (NTLA) , Achillion Pharmaceuticals Inc (ACHN) , and AveXis Inc (AVXS) .
Click here to see the complete history of Frank Verwiel’s form 4 insider trades.
Insider Ownership Summary of Frank Verwiel
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| NTLA | Intellia Therapeutics Inc | 2024-06-17 | director |
| ACHN | Achillion Pharmaceuticals Inc | 2020-01-28 | director |
| AVXS | AveXis Inc | 2018-05-15 | director |
Frank Verwiel Latest Holdings Summary
Frank Verwiel currently owns a total of 1 stock. Frank Verwiel owns 17,948 shares of Intellia Therapeutics Inc (NTLA) as of June 17, 2024, with a value of $298,834.
Latest Holdings of Frank Verwiel
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| NTLA | Intellia Therapeutics Inc | 2024-06-17 | 17,948 | 16.65 | 298,834 |
Holding Weightings of Frank Verwiel
Frank Verwiel Form 4 Trading Tracker
According to the SEC Form 4 filings, Frank Verwiel has made a total of 1 transactions in Intellia Therapeutics Inc (NTLA) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Intellia Therapeutics Inc is the sale of 1,505 shares on June 17, 2024, which brought Frank Verwiel around $37,625.
Insider Trading History of Frank Verwiel
- 1
Frank Verwiel Trading Performance
Frank Verwiel Ownership Network
Ownership Network List of Frank Verwiel
Ownership Network Relation of Frank Verwiel
Frank Verwiel Owned Company Details
What does Intellia Therapeutics Inc do?
Who are the key executives at Intellia Therapeutics Inc?
Frank Verwiel is the director of Intellia Therapeutics Inc. Other key executives at Intellia Therapeutics Inc include EVP & Chief Technical Officer Eliana Clark , EVP & Chief Scientific Officer Laura Sepp-lorenzino , and EVP & Chief Business Officer Derek Hicks .
Intellia Therapeutics Inc (NTLA) Insider Trades Summary
Over the past 18 months, Frank Verwiel made 1 insider transaction in Intellia Therapeutics Inc (NTLA) with a net sale of 1,505. Other recent insider transactions involving Intellia Therapeutics Inc (NTLA) include a net sale of 10,373 shares made by Eliana Clark , a net sale of 2,397 shares made by Muna Bhanji , and a net sale of 7,807 shares made by Laura Sepp-lorenzino .
In summary, during the past 3 months, insiders sold 2,012 shares of Intellia Therapeutics Inc (NTLA) in total and bought 0 shares, with a net sale of 2,012 shares. During the past 18 months, 62,207 shares of Intellia Therapeutics Inc (NTLA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 62,207 shares.
Intellia Therapeutics Inc (NTLA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Intellia Therapeutics Inc Insider Transactions
Frank Verwiel Mailing Address
Above is the net worth, insider trading, and ownership report for Frank Verwiel. You might contact Frank Verwiel via mailing address: C/o Intermune, Inc., 3280 Bayshore Blvd., Brisbane Ca 94005.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
